Advances in the development of vaccines against Marburg and Ebola viruses

Affiliations

¹ Laboratory of Infectious Disease, National Institute of Allergy & Infectious Diseases, National Institutes of Health, 50 South Drive, Bethesda, MA 20892, USA.
² Laboratory of Infectious Disease, National Institute of Allergy & Infectious Diseases, National Institutes of Health, 50 South Drive, Room 6505, Bethesda, MA 20892-8007, USA.

Peter L Collins et al. Future Virol. 2007 Nov.

. 2007 Nov;2(6):537-541.

doi: 10.2217/17460794.2.6.537. Epub 2007 Oct 31.

¹ Laboratory of Infectious Disease, National Institute of Allergy & Infectious Diseases, National Institutes of Health, 50 South Drive, Bethesda, MA 20892, USA.
² Laboratory of Infectious Disease, National Institute of Allergy & Infectious Diseases, National Institutes of Health, 50 South Drive, Room 6505, Bethesda, MA 20892-8007, USA.

No abstract available

References

1. Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB: Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg. Infect. Dis 8(5), 503–507 (2002). - PMC - PubMed
1. Volchkov VE, Volchkova VA, Muhlberger E et al.: Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 291(5510), 1965–1969 (2001). - PubMed
1. Enterlein S, Volchkov V, Weik M et al.: Rescue of recombinant Marburg virus from cDNA is dependent on nucleocapsid protein VP30. J. Virol 80(2), 1038–1043 (2006). - PMC - PubMed
1. Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A: Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 251(1), 28–37 (1998). - PubMed
1. Olinger GG, Hart MK: Protective immunity to Ebola infection by Venezuelian equine encephalitis virus replicons expressing Ebola virus proteins. Abstracts of the ICID Global Symposium. Filoviruses: Recent Advances and Future Challenges. International Centre for Infectious Diseases, Winnipeg, Canada, 17–19 September 2006.